We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Based on Genetic Biomarkers Detects Atrial Fibrillation

By LabMedica International staff writers
Posted on 15 Oct 2014
Print article
Image: ECG of atrial fibrillation (top) and normal sinus rhythm (bottom). The purple arrow indicates a P wave, which is lost in atrial fibrillation (Photo courtesy of Wikimedia Commons).
Image: ECG of atrial fibrillation (top) and normal sinus rhythm (bottom). The purple arrow indicates a P wave, which is lost in atrial fibrillation (Photo courtesy of Wikimedia Commons).
Heart disease researchers have developed a DNA-based blood test that identifies individuals with atrial fibrillation and predicts likelihood of suffering ischemic stroke.

Atrial fibrillation (AF) is the most common abnormal heart rhythm. It may cause no symptoms, but is often associated with palpitations, fainting, chest pain, or congestive heart failure. The cause of an individual's AF may not be identified. The risk of stroke is increased five-fold in individuals with AF. AF may be identified clinically when taking the pulse and its presence can be confirmed with an electrocardiogram (ECG) that demonstrates the absence of P waves and an irregular ventricular rate. AF may occur in episodes lasting from minutes to days or may be permanent in nature. Many medical conditions increase the risk of AF, in particular mitral stenosis (narrowing of the mitral valve of the heart).

Investigators at Lund University (Sweden) examined the possibility that genetic biomarkers could be used to detect AF. To this end they created an AF genetic risk score (AF-GRS) based on twelve genetic variants (single nucleotide polymorphisms or SNPs) in the human genome that were linked to increased risk of atrial fibrillation.

The investigators evaluated samples from In 27,471 participants of the Malmö Diet and Cancer Study, a prospective, community-based cohort, to assess the association of AF-GRS with incident AF and ischemic stroke. Median follow-up was 14.4 years for incident AF and 14.5 years for ischemic stroke.

During the follow-up period, 2160 participants experienced a first AF event and 1495 had a first ischemic stroke event. Participants in the top 20% of AF-GRS were at increased risk for incident AF and ischemic stroke when compared with the bottom 20%. Patients who had already been diagnosed with atrial fibrillation and carried the panel of 12 SNPs had their risk of stroke increased by a further 70%–80%.

"One in five people have a genetic weakness that means they have twice as high a risk of developing atrial fibrillation as those with a low genetic risk. This genetic risk is therefore one of the strongest risk factors for atrial fibrillation that we know of in people without overt cardiac disease. It increases the risk as much as high blood pressure, for example", said senior author Dr. Olle Melander, professor of internal medicine at Lund University. "In patients who are suspected of having temporary but recurrent episodes of atrial fibrillation, or in people with high blood pressure, it can be important for doctors to look at their genetic predisposition using a blood test. The test can give guidance as to how often and how intensively doctors need to screen for presence of atrial fibrillation in these individuals. We also consider that more widespread treatment of high blood pressure may be justified in those with a high genetic risk of atrial fibrillation."

The study was published in the October 2014 issue of the journal Stroke.

Related Links:

Lund University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.